SPRIM Global Investments (SGI) is the corporate venture capital arm of SPRIM, founded in 2008 and headquartered in Singapore. The firm specializes in clinical-stage life sciences and pharma services, deploying strategic capital into biotech, medtech, and digital health companies.
Deal activity decreased year-over-year (1 deal in the last 12 months vs 4 prior). Their most common stage is series-a (64% of deals). Average disclosed round size is $19.8M (across 10 rounds with reported amounts).
Portfolio
13
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
Elizabeth Wang
TrialCap, Director, Credit Structuring
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
14 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 ErVimmune | Series A | $19.8M | Jan 2026 |
 Vaxxas | Series D | $49.2M | Aug 2025 |
| AAzaleavision | Series A | — | Apr 2025 |
 Lattice Medical | Unknown | — | Jan 2025 |
| CCilcare | Series A | — | Dec 2024 |
| DDoron Therapeutics | Series A | $11M | Nov 2024 |
| PProta Therapeutics | Unknown | $21M | Jan 2024 |
| DDoron Therapeutics | Series A | $11M | Jan 2024 |
| SSpexis AG | Seed | $2.5M | Aug 2023 |
 RegASK | Series A | $10M | Dec 2022 |
| AAUM Biosciences | Series A | $27M | Oct 2021 |
| OObvioHealth | Unknown | $31M | Jul 2021 |
 Azalea Vision | Series A | — | — |
 Rheumagen | Series A | $15M | — |
Top Co-Investors
Bpifrance1 shared
Scale Venture Partners1 shared
Seventure Partners1 shared
Elaia1 shared
Monograph Capital1 shared
Marbruck Investments1 shared
Oldslip1 shared
Blast.Club1 shared
Last updated: 20 October 2026